Dataset Information

Radiosensitivity in breast cancer assessed by the histone ?-H2AX and 53BP1 foci.

ABSTRACT:

Background

High expression of constitutive histone ?-H2AX, a sensitive marker of DNA damage, might be indicative of defective DNA repair pathway or genomic instability. 53BP1 (p53-binding protein 1) is a conserved checkpoint protein with properties of a DNA double-strand breaks sensor. This study explores the relationship between the clinical radiosensitivity of tumor patients and the expression/induction of ?-H2AX and 53BP1 in vitro.

Methods

Using immunostaining, we assessed spontaneous and radiation-induced foci of ?-H2AX and 53 BP1 in peripheral blood mononuclear cells derived from unselected breast cancer (BC) patients (n=57) undergoing radiotherapy (RT). Cells from apparently healthy donors (n=12) served as references.

Results

Non-irradiated cells from controls and unselected BC patients exhibited similar baseline levels of DNA damage assessed by ?-H2AX and 53BP1 foci. At the same time, the ?-H2AX assay of in vitro irradiated cells revealed significant differences between the control group and the group of unselected BC patients with respect to the initial (0.5?Gy, 30?min) and residual (2?Gy, 24?h post-radiation) DNA damage. The numbers of 53BP1 foci analyzed in 35 BC patients were significantly higher than in controls only in case of residual DNA damage. A weak correlation was found between residual foci of both proteins tested. In addition, cells from cancer patients with an adverse acute skin reaction (grade 3) to RT showed significantly increased radiation-induced ?-H2AX foci and their protracted disappearance compared to the group of BC patients with normal skin reaction (grade 0-1). The mean number of ?-H2AX foci after 5 clinical fractions was significantly higher than that before RT, especially in clinically radiosensitive patients.

Conclusions

The ?-H2AX assay may have potential for screening individual radiosensitivity of breast cancer patients.

Trial registration

http://www.krebshilfe.de/wir-foerdern.html.

SUBMITTER: Djuzenova CS

PROVIDER: S-EPMC3653697 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Radiosensitivity in breast cancer assessed by the histone γ-H2AX and 53BP1 foci.

Djuzenova Cholpon S CS Elsner Ines I Katzer Astrid A Worschech Eike E Distel Luitpold V LV Flentje Michael M Polat Bülent B

Radiation oncology (London, England) 20130424

<h4>Background</h4>High expression of constitutive histone γ-H2AX, a sensitive marker of DNA damage, might be indicative of defective DNA repair pathway or genomic instability. 53BP1 (p53-binding protein 1) is a conserved checkpoint protein with properties of a DNA double-strand breaks sensor. This study explores the relationship between the clinical radiosensitivity of tumor patients and the expression/induction of γ-H2AX and 53BP1 in vitro.<h4>Methods</h4>Using immunostaining, we assessed spon ...[more]

PMID: 23617930

Similar Datasets

Project description:BackgroundIn response to DNA double-strand breaks, the histone protein H2AX becomes phosphorylated at its C-terminal serine 139 residue, referred to as ?-H2AX. Formation of ?-H2AX foci is associated with recruitment of p53-binding protein 1 (53BP1), a regulator of the cellular response to DNA double-strand breaks. ?-H2AX expression in peripheral blood mononuclear cells (PBMCs) was recently proposed as a diagnostic and disease activity marker for multiple sclerosis (MS).ObjectiveTo evaluate the significance of ?-H2AX and 53BP1 foci in PBMCs as diagnostic and disease activity markers in patients with clinically isolated syndrome (CIS) and early relapsing-remitting MS (RRMS) using automated ?-H2AX and 53BP1 foci detection.MethodsImmunocytochemistry was performed on freshly isolated PBMCs of patients with CIS/early RRMS (n = 25) and healthy controls (n = 27) with ?-H2AX and 53BP1 specific antibodies. Nuclear ?-H2AX and 53BP1 foci were determined using a fully automated reading system, assessing the numbers of ?-H2AX and 53BP1 foci per total number of cells and the percentage of cells with foci. Patients underwent contrast enhanced 3 Tesla magnetic resonance imaging (MRI) and clinical examination including expanded disability status scale (EDSS) score. ?-H2AX and 53BP1 were also compared in previously frozen PBMCs of each 10 CIS/early RRMS patients with and without contrast enhancing lesions (CEL) and 10 healthy controls.ResultsThe median (range) number of ?-H2AX (0.04 [0-0.5]) and 53BP1 (0.005 [0-0.2]) foci per cell in freshly isolated PBMCs across all study participants was low and similar to previously reported values of healthy individuals. For both, ?-H2AX and 53BP1, the cellular focus number as well as the percentage of positive cells did not differ between patients with CIS/RRMS and healthy controls. ?-H2AX and 53BP1 levels neither correlated with number nor volume of T2-weighted lesions on MRI, nor with the EDSS. Although ?-H2AX, but not 53BP1, levels were higher in previously frozen PBMCs of patients with than without CEL, ?-H2AX values of both groups overlapped and ?-H2AX did not correlate with the number or volume of CEL.Conclusion?-H2AX and 53BP1 foci do not seem to be promising diagnostic or disease activity biomarkers in patients with early MS. Lymphocytic DNA double-strand breaks are unlikely to play a major role in the pathophysiology of MS.